MerckMRK
MRK
0
Funds holding %
of 7,390 funds
0
Analysts bullish %
of 9 analysts
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
71% more first-time investments, than exits
New positions opened: 353 | Existing positions closed: 206
15% more call options, than puts
Call options by funds: $1.8B | Put options by funds: $1.56B
2% more funds holding
Funds holding: 3,440 [Q3] → 3,507 (+67) [Q4]
1.07% more ownership
Funds ownership: 76.66% [Q3] → 77.72% (+1.07%) [Q4]
11% less capital invested
Capital invested by funds: $221B [Q3] → $197B (-$24.2B) [Q4]
17% less repeat investments, than reductions
Existing positions increased: 1,293 | Existing positions reduced: 1,551
36% less funds holding in top 10
Funds holding in top 10: 111 [Q3] → 71 (-40) [Q4]
Research analyst outlook
9 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$96
9%
upside
Avg. target
$111
26%
upside
High target
$120
37%
upside
9 analyst ratings
5 positive
56%
4 neutral
44%
0 negative
0%
Deutsche Bank James Shin 40% 1-year accuracy 2 / 5 met price target | 20%upside $105 | Hold Downgraded | 18 Feb 2025 |
Guggenheim Vamil Divan 56% 1-year accuracy 15 / 27 met price target | 31%upside $115 | Buy Maintained | 12 Feb 2025 |
B of A Securities Tim Anderson 50% 1-year accuracy 7 / 14 met price target | 28%upside $112 | Buy Maintained | 5 Feb 2025 |
BMO Capital Evan David Seigerman 32% 1-year accuracy 6 / 19 met price target | 9%upside $96 | Market Perform Maintained | 5 Feb 2025 |
Citigroup Andrew Baum 67% 1-year accuracy 4 / 6 met price target | 31%upside $115 | Buy Maintained | 5 Feb 2025 |
Financial journalist opinion
Based on 311 articles about MRK published over the past 30 days
Neutral
Accesswire
1 hour ago
Merck & Co., Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before April 14, 2025 to Discuss Your Rights - MRK
NEW YORK, NY / ACCESS Newswire / March 27, 2025 / If you suffered a loss on your Merck & Co., Inc. (NYSE:MRK) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/merck-co-inc-lawsuit-submission-form?prid=139205&wire=1 or contact Joseph E. Levi, Esq.
Neutral
Accesswire
2 hours ago
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of April 14, 2025 in Merck & Co., Inc. Lawsuit - MRK
NEW YORK, NY / ACCESS Newswire / March 27, 2025 / If you suffered a loss on your Merck & Co., Inc. (NYSE:MRK) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/merck-co-inc-lawsuit-submission-form?prid=139197&wire=1 or contact Joseph E. Levi, Esq.
Neutral
Accesswire
2 hours ago
TOP RANKED ROSEN LAW FIRM Encourages Merck & Co., Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - MRK
NEW YORK, NY / ACCESS Newswire / March 27, 2025 / WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Merck & Co., Inc. (NYSE:MRK) between February 3, 2022 and February 3, 2025, both dates inclusive (the "Class Period"), of the important April 14, 2025 lead plaintiff deadline. SO WHAT: If you purchased Merck securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
Neutral
GlobeNewsWire
2 hours ago
Investors who lost money on Merck & Co., Inc. (MRK) should contact Levi & Korsinsky about pending Class Action - MRK
NEW YORK, March 27, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Merck & Co., Inc. ("Merck" or the "Company") (NYSE: MRK) of a class action securities lawsuit.
Neutral
GlobeNewsWire
2 hours ago
ROSEN, LEADING TRIAL ATTORNEYS, Encourages Merck & Co., Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – MRK
NEW YORK, March 27, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Merck & Co., Inc. (NYSE: MRK) between February 3, 2022 and February 3, 2025, both dates inclusive (the “Class Period”), of the important April 14, 2025 lead plaintiff deadline. SO WHAT: If you purchased Merck securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
Positive
Zacks Investment Research
3 hours ago
Merck Gets EC Nod for 21-Valent Pneumococcal Jab Capvaxive
The European Commission approves MRK's pneumococcal 21-valent conjugate vaccine, Capvaxive, for pneumococcal vaccination in adults.
Neutral
PRNewsWire
3 hours ago
Merck & Co (MRK) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
LOS ANGELES , March 27, 2025 /PRNewswire/ -- Glancy Prongay & Murray LLP announces that investors with losses have opportunity to lead the securities fraud class action lawsuit against Merck & Co ("Merck" or the "Company") (NYSE: MRK). IF YOU SUFFERED A LOSS ON YOUR MERCK INVESTMENTS, CLICK HERE BEFORE APRIL 14, 2025 (LEAD PLAINTIFF DEADLINE) TO PARTICIPATE IN THE SECURITIES FRAUD LAWSUIT What Is The Lawsuit About?
Positive
Reuters
4 hours ago
Merck plans US to launch subcutaneous version of Keytruda on October 1
Merck & Co said on Thursday that it plans to launch a subcutaneously injected version of its blockbuster cancer immunotherapy Keytruda in the U.S. on October 1, and expects to hit peak adoption rates of the new version within two years.
Neutral
Business Wire
4 hours ago
Merck's Investigational Subcutaneous Pembrolizumab With Berahyaluronidase Alfa Demonstrates Noninferior Pharmacokinetics Compared to Intravenous (IV) KEYTRUDA® (pembrolizumab) in Pivotal 3475A-D77 Trial
RAHWAY, N.J.--(BUSINESS WIRE)-- #MRK--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the first data presentation from the pivotal 3475A-D77 Phase 3 trial, evaluating the subcutaneous administration of pembrolizumab, together with berahyaluronidase alfa (MK-3475A; from now on referred to as “subcutaneous pembrolizumab”). Berahyaluronidase alfa is a variant of human hyaluronidase developed and manufactured by Alteogen Inc. These results are being presented today.
Positive
Investors Business Daily
4 hours ago
Merck's Biggest Moneymaker Could Get Even Bigger. But Will It Help Downtrodden Shares?
The FDA is due to make an approval decision on injectable Keytruda by mid-September. The move could bolster downtrodden Merck stock.
Charts implemented using Lightweight Charts™